Lu Ruixin, Glaser Natalie, Sartipy Ulrik, Dismorr Michael
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Department of Cardiology, Stockholm South General Hospital, Stockholm, Sweden.
JACC Adv. 2024 Jul 18;3(8):101110. doi: 10.1016/j.jacadv.2024.101110. eCollection 2024 Aug.
Permanent pacemaker implantation is associated with an increased risk of mortality and heart failure after surgical aortic valve replacement (SAVR).
The purpose of this study was to analyze long-term prognosis of permanent pacemaker implantation following SAVR on low-risk patients.
This nationwide, population-based, observational cohort study included all patients who underwent SAVR in Sweden between 2001 and 2018 with low surgical risk, defined as logistic EuroSCORE I <10% or EuroSCORE II <4%. Patients received a permanent pacemaker implantation within 30 days after SAVR. Main outcomes were all-cause mortality, heart failure hospitalization, and endocarditis. Regression standardization addressed confounding.
We included 19,576 patients with low surgical risk. Of these, 732 (3.7%) patients received a permanent pacemaker within 30 days after SAVR. The mean age was 68 years and 33% were women. We found no difference in all-cause mortality between patients who received a pacemaker compared to those who did not (absolute survival difference at 17 years: 0.1% (95% CI: -3.6% to 3.8%). After 17 years, the estimated cumulative incidence of heart failure in patients who received a pacemaker was 28% (95% CI: 24%-33%) vs 20% (95% CI: 19%-22%) in patients who did not (absolute difference 8.2% [95% CI: 3.8%-13%]). We found no difference in endocarditis between the groups.
We found an increased incidence of heart failure in patients with low surgical risk who received a permanent pacemaker after SAVR. Permanent pacemaker implantation was not associated with all-cause mortality or endocarditis. Efforts should be made to avoid the need for permanent pacemaker following SAVR.
永久性起搏器植入与外科主动脉瓣置换术(SAVR)后死亡率和心力衰竭风险增加相关。
本研究旨在分析低风险患者SAVR后永久性起搏器植入的长期预后。
这项基于全国人群的观察性队列研究纳入了2001年至2018年在瑞典接受SAVR且手术风险低的所有患者,手术风险低定义为逻辑欧洲心脏手术风险评估系统I<10%或欧洲心脏手术风险评估系统II<4%。患者在SAVR后30天内接受永久性起搏器植入。主要结局为全因死亡率、心力衰竭住院和心内膜炎。回归标准化处理了混杂因素。
我们纳入了19576例手术风险低的患者。其中,732例(3.7%)患者在SAVR后30天内接受了永久性起搏器植入。平均年龄为68岁,33%为女性。我们发现接受起搏器植入的患者与未接受者的全因死亡率无差异(17年时的绝对生存差异:0.1%[95%CI:-3.6%至3.8%])。17年后,接受起搏器植入患者的心力衰竭估计累积发生率为28%(95%CI:24%-33%),而未接受者为20%(95%CI:19%-22%)(绝对差异8.2%[95%CI:3.8%-13%])。我们发现两组在心内膜炎方面无差异。
我们发现SAVR后接受永久性起搏器植入的低手术风险患者心力衰竭发生率增加。永久性起搏器植入与全因死亡率或心内膜炎无关。应努力避免SAVR后需要植入永久性起搏器。